Navigation Links
Breast Cancer Drug May Harm the Heart More Than Thought
Date:8/31/2012

By Kathleen Doheny
HealthDay Reporter

THURSDAY, Aug. 30 (HealthDay News) -- Women with breast cancer who are treated with the cancer drug Herceptin may have more long-term cardiac problems than experts have thought, new research suggests.

It has been known that women treated with anti-cancer drugs known as anthracyclines and Herceptin (trastuzumab) are at higher risk for heart failure and cardiomyopathy, a weakening of the heart muscle.

But, that information on risks has come primarily from clinical trials, which typically exclude women aged 70 and older and those with co-existing chronic diseases, so it doesn't necessarily give a real-world picture, the researchers noted.

"The risk of heart failure associated with these drugs might be higher than what has been shown in clinical trials," explained study author Erin Aiello Bowles, an epidemiologist at Group Health Research Institute, in Seattle. Her report is published online Aug. 30 in the Journal of the National Cancer Institute.

Bowles and her colleagues evaluated 12,500 women diagnosed with invasive breast cancer from 1999 through 2007 in eight different health systems. The patients' average age was 60. The follow-up time ranged from more than two years to nearly seven.

The researchers used data from medical records and other sources to track type of cancer treatment and diagnoses of cardiac problems.

The risk of heart failure was 1.4 times higher in those treated only with an anthracycline at the five-year mark. That was about the same increase as those treated with other types of cancer drugs. However, those on Herceptin alone had more than four times the risk of heart problems compared to those who did not take the medication, the study stated.

And, the biggest increase in risk was seen in those on both anthracyclines and Herceptin. Those patients showed a sevenfold increased risk at the five-year mark, the researchers said.<
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. More heart problems with 2 chemo drugs for breast cancer
2. Possible therapy for tamoxifen resistant breast cancer identified
3. Exploring exercise benefits for breast cancer patients
4. Breast Cancer Drug Might Help Men on Prostate Cancer Therapy
5. Daily Aspirin May Help Fight Prostate Cancer, But Not Breast Cancer
6. Excess Pounds Raise Risk of Breast Cancer Recurrence, Death: Study
7. Johns Hopkins team finds ICU misdiagnoses may account for as many annual deaths as breast cancer
8. Lack of sleep found to be a new risk factor for aggressive breast cancers
9. Obese and overweight women face increased risk of recurrence of most common type of breast cancer
10. RI Hospital researcher: Older women may not benefit from radiotherapy after breast surgery
11. New survey: Women want to SEE breast reconstruction results before cancer surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breast Cancer Drug May Harm the Heart More Than Thought
(Date:7/9/2014)... network of signals active in almost all types of ... overdrive, and may help fuel a tumour,s uncontrolled growth, ... Cancer Research, London, identified a molecular trigger responsible for ... the cellular factory that makes the building blocks cancer ... the TOR signalling pathway, called SREBP, controls the flow ...
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
(Date:7/9/2014)... ITHACA, N.Y. Although feelings are personal and ... standard code that objectively represents emotions across different ... study by Cornell University neuroscientist Adam Anderson. , ... within the orbitofrontal cortex, an area of the ... neural code which captures an individual,s subjective feeling," ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... ... ... Noni International (TNI) announced that Tahitian Noni® Bioactive Beverages™ contain iridoids —a bioactive ... for over 50 years and now 12 unique iridoids have been identified in the ...
... ... and after pictures and a directory for patients looking to find a plastic surgeon ... laser skin care. , ... (PRWEB) March 11, 2010 -- MyCosmeticProcedures.com is a new website focused ...
... , ... Technology Leadership with Largest Number of Highly Automated QT(sm) and QT Beat-to-Beat(sm) Studies ... Rochester, N.Y. (PRWEB) ... services and QT analysis, announced today that a top 10 pharmaceutical company has awarded ...
... LocalITCompanies.com ... be expanding nationwide. Local IT Companies connects businesses with up to three pre-screened IT service ... ... owners are entrenched in their own day to day business building operations and the thought ...
... Delphi ... Hospital in Hayward, California , ... Morrisville, NC (PRWEB) March 11, 2010 -- Delphi Healthcare Partners, Inc. ( ... provide a comprehensive OB/Gyn solution. With help from Delphi, St. Rose is in ...
... number of younger minority adults receiving medical care in settings ... the healthcare safety net). Poor, minority adults with moderate to ... to progress to kidney failure than non-Hispanic whites. These are ... Clinical Journal of the American Society of Nephrology (CJASN). ...
Cached Medicine News:Health News:12 Unique Iridoids Have Been Found in Noni Fruit 2Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 2Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 3Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 4Health News:Top 10 Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 3Health News:Delphi Healthcare Partners Announces New Obstetrics/Gynecology Programs in Hayward, California 2Health News:Study: Kidney disease a big risk for younger, low-income minorities 2
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage ... positive, statistically significant top-line results from its ANCHOR trial for ... met its primary and secondary efficacy endpoints for both the ... The purpose of the ANCHOR trial was to demonstrate that ...
... and SYDNEY, April 15, 2011 HeartWare International, ... a leading innovator of less invasive, miniaturized circulatory ... advanced heart failure, today announced the presentation of ... transplantation (BTT) study, ADVANCE, showing 180-day survival, using ...
Cached Medicine Technology:Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 3Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 4Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 5Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 6Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 7Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 8HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5
Rosenbaum card fits in the pocket (3.5 by 6.5") and shows point, Jaeger and distance equivalents from 20/800 to 20/20. Uses numbers, directional Es and XO patterns. For use at 14" (35 mm). Includes f...
... contemporary reading card was designed by James ... of near point exercises including words, numbers ... 20/260, 20/200, 20/100, 20/65, 20/50, 20/40, 20/30, ... reading in English and metric, Jaeger, point ...
Standard reading test. "walked regularly..."...
Standard reading test. "Children should be..."...
Medicine Products: